Board tracked Radar started tracking this company’s job board (56 open jobs at last check). source ↗
Trial start 1: A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer source ↗
Trial start 1: A Phase 1 Study of IM-1617 in Participants With Advanced Cancer source ↗
Trial start Phase 1: A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants source ↗
Raise Follow-on offering: $400M (total, as published), announced Dec 16, 2025. Source: SEC filing. source ↗
Trial start Phase 1: A Varegacestat Hepatic Impairment Study source ↗
Trial start 1: A Phase 1 Study of IM-1021 in Participants With Advanced Cancer source ↗
Trial start 1: A Phase 1 Mass Balance Study of Varegacestat source ↗
Trial start Phase 1: A Cardiac Liability Study of Varegacestat in Healthy Participants source ↗
Raise Follow-on offering: $150M (total, as published), announced Jan 29, 2025. Source: SEC filing. source ↗
Trial start 1: A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants source ↗
Trial start Phase 1: IMM-BCP-01 in Mild to Moderate COVID-19 source ↗
Trial start Phase 2/Phase 3: A Study of AL102 in Patients With Progressing Desmoid Tumors source ↗
Upcoming milestones
2028-05 (ESTIMATED) · 1 · A Phase 1 Study of IM-1021 in Participants With Advanced Cancer · NCT06823167
2029-01 (ESTIMATED) · 1 · A Phase 1 Study of IM-1617 in Participants With Advanced Cancer · NCT07578571
2029-12 (ESTIMATED) · 1 · A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer · NCT07505771
Estimated primary completion per ClinicalTrials.gov. Dates move.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.